The Latest Breaking News from Cencora

Meta Platforms ushered a follow-on buy point near 564.

Cencora is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth in the company’s bottom-line figure.

Cencora has outperformed other healthcare stocks over the past year and analysts remain bullish about the stock’s prospects.

Cencora has outperformed the broader market over the past year, and Wall Street analysts remain bullish about the stock's prospects.

McKesson earnings beat estimates, but the drug and health supplies distribution giant badly missed sales estimates.

Ransomware attacks are becoming more common, and more lucrative, report finds.

With Cencora gearing up to release its third-quarter earnings later this month, analysts project a single-digit earnings growth.

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.09%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.19%. Stock indexes recovered from early losses on Thursday and settled slightly higher. Stocks found...

Cencora stock and other drug distributors fell on Wednesday, hit by Walgreens results, not the ruling that killed an opioid settlement.

The S&P 500 Index ($SPX ) (SPY ) today is down -0.03%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.10%. Stock indexes today recovered from early losses and are mixed after weaker-than-expected US economic...

Shares of Cencora have outperformed the broader healthcare sector over the past year, and Wall Street analysts are bullish about the stock’s prospects.